Aldosterone-to-Renin Ratio as a Diagnostic and Prognostic Marker in Resistant Hypertension: Insights from a Retrospective Observational Study on Age, Hormonal Dysregulation, and Anthropometric Correlates
DOI:
https://doi.org/10.22270/ajprd.v12i6.1494Abstract
Resistant hypertension (RH) presents a significant clinical challenge, often requiring multi-faceted management strategies. This study aimed to evaluate the utility of the Aldosterone-to-Renin Ratio (ARR) as a diagnostic tool in identifying potential hormonal contributors to RH. Methods: We retrospectively analysed data from 852 patients diagnosed with RH at Nandha College of Pharmacy, Erode between December 2023 and March 2024. Patients met specific criteria for RH, including uncontrolled blood pressure despite treatment with three or more antihypertensive agents from different classes, including a diuretic. Exclusion criteria included secondary causes of hypertension. ARR was calculated by dividing serum aldosterone concentration by plasma renin activity, with a ratio ≥ 20 considered suggestive of primary aldosteronism. Results: A strong association between advancing age and RH was observed, with mean age progressively increasing from 25.67 years in the youngest age group to 76.12 years in the oldest. Approximately 59.15% of hypertensive patients had RH, with nearly half (46.63%) attributable to evident secondary causes. Notably, the remaining 53.37% lacked a clear secondary cause. Analysis of ARR revealed a statistically significant positive correlation with age, suggesting a potential link between aging and hormonal dysregulation within the renin-angiotensin-aldosterone system (RAAS). Patients with RH also exhibited higher body weights, BMI, and waist circumferences compared to those with controlled hypertension. Conclusion: This study suggests that ARR may be a valuable tool for identifying potential hormonal contributors to RH, particularly in older patients. The observed association between age, ARR, and RH highlights the need for age-tailored management strategies that incorporate hormonal assessment and address modifiable risk factors such as obesity. Further research is warranted to validate these findings and explore the clinical implications of ARR-guided management in RH.
Downloads
References
Myat A, Redwood S R, Qureshi A C, Spertus J A, Williams B. Resistant hypertension BMJ 2012; 345 :e7473 doi:10.1136/bmj.e7473
Quencer, Keith B et al. “Primary Aldosteronism.” American family physician vol. 2023;108(3): 273-277.
Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016; 32:569–88. doi:10.1016/j.cjca.2016.02.066.
Williams B, Macdonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015; 386:2059–68. doi:10.1016/S0140-6736(15)00257-3.
Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999; 48:756–60. doi:10.1046/j.1365-2125.1999.00062.x.
Browne GA, Griffin TP, O’Shea PM, et al. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone–renin ratio in chronically treated hypertension. Clin Endocrinol (Oxf). 2016; 84:325–31. doi:10.1111/cen.12953.
Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone–renin ratio. Am J Kidney Dis. 2001; 37:699–705. doi:10.1053/ajkd.2001.22616.
Baudrand R, Guarda FJ, Torrey J, et al. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab. 2016; 101:3989–96. doi:10.1210/jc.2016-2274.
Kline GA, Pasieka JL, Harvey A, et al. High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false-positive diagnoses. J Clin Hypertens (Greenwich). 2014;16:488–96. doi:10.1111/jch.12303.
Nanba K, Tamanaha T, Nakao K, et al. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab. 2012;97:1688–94. doi:10.1210/jc.2011-3271.
Giacona JM, Kositanurit W, Vongpatanasin W. Management of Resistant Hypertension—An Update. JAMA Intern Med. 2024; 184(4):433–434. doi:10.1001/jamainternmed.2023.8555
Flack, J.M., Buhnerkempe, M.G. & Moore, K.T. Resistant Hypertension: Disease Burden and Emerging Treatment Options. Curr Hypertens Rep (2024).
Luis M Ruilope, Elena Rodríguez-Sánchez, José Alberto Navarro-García, Julian Segura, Alberto Órtiz, Alejandro Lucia, Gema Ruiz-Hurtado, Resistant hypertension: new insights and therapeutic perspectives, European Heart Journal - Cardiovascular Pharmacotherapy, 2020; 6(3):188–193,
Mahmud A, Mahgoub M, Hall M, et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005; 18:1631–5. doi:10.1016/j.amjhyper.2005.06.003.
Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341:709–17. doi:10.1056/NEJM199909023411001.
Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–36. doi:10.1111/j.1523-1755.2005.00748.x.
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351:543–51.
Barnes BJ, Howard PA. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother. 2005; 39:68–76.
Kline GA, Pasieka JL, Harvey A, et al. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes. Ann Surg Oncol. 2013; 20:2274–8.
Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008; 168:80–5.
Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006; 295:2638–45.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Muktai N. Rudrurkar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.